Maxcyte (DI) (MXCT)

Index:

FTSE AIM 100

 165.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 405.00
  • 52 Week Low: 162.10
  • Currency: UK Pounds
  • Shares Issued: 106.42m
  • Volume: 3,016
  • Market Cap: £176.12m

Latest ShareCast News

MaxCyte signs SPL deal with TG Therapeutics

By Josh White

Date: Wednesday 12 Feb 2025

(Sharecast News) - MaxCyte announced the signing of a strategic platform licence agreement with TG Therapeutics on Wednesday, granting the biopharmaceutical company access to its 'Flow Electroporation' technology and 'ExPERT' platform to support the development and commercialisation of Azer-cel, an allogeneic CD19 CAR T cell therapy for autoimmune diseases.

MaxCyte announces acquisition of SeQure Dx

By Josh White

Date: Thursday 30 Jan 2025

(Sharecast News) - MaxCyte announced on Thursday that it has acquired SeQure Dx, a specialist in on-target and off-target editing assessment services for cell and gene therapies, in a move aimed at broadening its offerings in the cell engineering space.

MaxCyte flags full-year revenue at top end of expectations

By Josh White

Date: Monday 13 Jan 2025

(Sharecast News) - Cell-engineering platform technology company MaxCyte said in an update on Friday that it expected core revenue for the fourth quarter to range between $8.3m and $8.5m, up from $7.2m in the same period last year.

MaxCyte upgrades revenue guidance after operatio... 09-Dec-2024 ShareCast
MaxCyte appoints new chief commercial officer 10-Oct-2024 ShareCast
MaxCyte enters licence agreement with Kamau Ther... 16-Sep-2024 ShareCast
MaxCyte reports solid second-quarter performance 07-Aug-2024 ShareCast
MaxCyte reports strong first quarter 08-May-2024 ShareCast
MaxCyte reports strong fourth quarter as full-ye... 13-Mar-2024 ShareCast
MaxCyte flags lower 2023 revenue, flat 2024 growth 05-Mar-2024 ShareCast
MaxCyte flags uptick in total fourth-quarter rev... 09-Jan-2024 ShareCast
Maher Masoud starts as MaxCyte president, CEO 02-Jan-2024 ShareCast
MaxCyte announces new CEO, updates revenue guida... 12-Dec-2023 ShareCast
MaxCyte joins Alliance for mRNA Medicines 16-Nov-2023 ShareCast
MaxCyte lowers full-year guidance after weaker t... 05-Oct-2023 ShareCast
MaxCyte signs licence deal with Vittoria Biother... 10-Jul-2023 ShareCast
MaxCyte inks platform licensing deal with Lyell 06-Jul-2023 ShareCast
MaxCyte revises guidance after weaker first quar... 11-May-2023 ShareCast
MaxCyte installs Douglas Swirsky as its new fina... 28-Mar-2023 ShareCast
MaxCyte expecting strong 2023 after decent results 16-Mar-2023 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Maxcyte (DI) Market Data

Currency UK Pounds
Share Price 165.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 405.00
52 Week Low 162.10
Volume 3,016
Shares Issued 106.42m
Market Cap £176.12m

Maxcyte (DI) Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend Not Available
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 3
Buy 3
Neutral 0
Sell 0
Strong Sell 0
Total 6
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Maxcyte (DI) Dividends

No dividends found

Trades for 03-Jun-2025

Time Volume / Share Price
15:50 764 @ 162.18p
14:22 1,000 @ 162.18p
13:01 95 @ 162.18p
11:52 205 @ 162.13p
10:02 40 @ 162.11p

Top of Page